Sanofi Consumer Healthcare India Ltd (SANOFICONR)
₹3,442.30
Mkt cap
₹7,928 Cr
P/E ratio
28.30
P/B
22.80
Div yield
2.18%
ROE
71.60%
ROCE
89.90%
EPS (TTM)
₹121.64
Book value
₹151
52W range
3,168–5,255
Sector
Healthcare
Price history
Previous close
Incorporated in 2023, Sanofi Consumer Healthcare India Ltd manufactures and trading of drugs & pharmaceutical products. [1] It is a division of Sanofi, a global pharmaceutical company, focusing on over-the-counter (OTC) and consumer healthcare products. [2]
NSE SANOFICONRBSE 544250
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthHigh
TechnicalsBearish
52-week range
−34.49% from high₹3,442
₹3,168+8.65% from low₹5,255
Current
₹3,442.30
Prev close
₹3,468.00
Day
−0.74%
Price performance
1D
−1.90%
1W
+6.05%
1M
−12.02%
3M
−26.36%
6M
−28.95%
1Y
−26.81%
YTD
−25.10%
Financials
Revenue, profit & margin
P/E ratio
28.3×
SANOFICONR is 17% below the sector median of 34.0×
SANOFICONR28.3×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 210 | 225 | 222 | 172 | 160 | 171 | 173 | 221 | 234 | 251 | 229 | 236 | 263 | |
| Expenses | 116 | 135 | 140 | 109 | 97 | 109 | 109 | 151 | 149 | 161 | 140 | 146 | 161 | |
| Operating Profit | 95 | 90 | 82 | 64 | 63 | 62 | 64 | 70 | 85 | 90 | 89 | 89 | 102 | |
| OPM % | 45% | 40% | 37% | 37% | 39% | 36% | 37% | 32% | 36% | 36% | 39% | 38% | 39% | |
| Other Income | 1 | 1 | 3 | -24 | 3 | 2 | 5 | 12 | 3 | 5 | 6 | 6 | 4 | |
| Interest | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | |
| Profit before tax | 95 | 90 | 84 | 39 | 61 | 63 | 67 | 79 | 84 | 90 | 91 | 92 | 103 | |
| Tax % | 25% | 24% | 25% | 25% | 26% | 29% | 25% | 23% | 25% | 27% | 25% | 25% | 25% | |
| Net Profit | 71 | 68 | 63 | 29 | 45 | 44 | 50 | 61 | 63 | 66 | 68 | 69 | 77 | |
| EPS in Rs | 12.59 | 19.54 | 19.24 | 21.71 | 26.36 | 27.31 | 28.87 | 29.44 | 29.87 | 33.26 | ||||
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202671.27%Promoter
Promoters71.27%
FIIs2.48%0.12
DIIs18.03%0.18
Public8.22%0.06
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Sanofi Consumer | ₹3,442.30 | 28.34 | 7,928 | 2.18% | 77 | +21.78% | 263 | +12.48% | 89.93% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports2
Concall transcripts2
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 29 Oct - Copy of Newspaper Publication of Unaudited Financial Results for the quarter and nine months ended 30th September 2026 is enclosed.Announcement under Regulation 30 (LODR)-Press Release / Media Release 28 Oct - Sanofi Consumer Healthcare India approved Q3 and nine-month FY26 results; Q3 revenue ₹2,631 million, profit ₹1,027 million.Results - Financial Results For September 30, 2026 28 Oct - Q3 FY26 revenue rose 12% to ₹2,631 million; nine-month revenue rose 16% to ₹7,280 million.Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, 28Th October 2026 28 Oct - Q3 FY26 revenue rose 12% to ₹2,631 million; nine-month revenue grew 16% to ₹7,280 million.Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 30Th September 2026. 22 Oct - Board meeting on 28 October 2026 to approve Q2 and nine-month FY2026 unaudited results; trading window closed until 30 October.